Invesco Biotechnology & Genome ETF (PBE) is a Invesco ETF with a 0.59% expense ratio, 33 holdings and $429MM in net assets. Largest sector: Healthcare (100%).
Fee
0.59%
expense ratio
Net assets
$429MM
Launched
Jun 23, 2005
Holdings
33
as of Oct 24, 2026
Top 10 weight
49.2%
largest ten holdings
Largest sector
Healthcare
100.0%
Yield
30-day SEC -0.18%
as of Oct 22, 2026
Benchmark
Dynamic Biotechnology & Genome Intellidex Index
PBE's holdings are as of Oct 24, 2026.
Healthcare
100.0%
1
NTRA
Natera
6.00%
2
ILMN
ILLUMINA
5.99%
3
BIIB
BIOGEN
5.68%
4
GILD
GILEAD SCIENCES
5.24%
5
RPRX
ROYALTY PHARMA
5.14%
6
AMGN
AMGEN
4.96%
7
REGN
REGENERON PHARMACEUTICALS
4.83%
8
VRTX
VERTEX PHARMACEUTICALS
4.74%
9
MRNA
MODERNA
3.43%
10
QIA
QIAGEN NV
3.15%
11
HALO
Halozyme Therapeutics
3.13%
12
EXEL
Exelixis
3.10%
13
UTHR
United Therapeutics
3.09%
14
VCYT
VERACYTE
2.97%
15
NVAX
Novavax
2.80%
16
VCEL
Vericel
2.68%
17
TGTX
TG Therapeutics
2.66%
18
RGEN
Repligen
2.65%
19
SRPT
Sarepta Therapeutics
2.55%
20
NBIX
Neurocrine Biosciences
2.54%
21
PTGX
Protagonist Therapeutics
2.51%
22
LEGN
LEGEND BIOTECH ADR REP
2.47%
23
INCY
INCYTE
2.43%
24
BMRN
BioMarin Pharmaceutical
2.31%
25
ANAB
AnaptysBio
2.28%
1–25 of 33
Funds listed by how much of their largest holdings they share with PBE — not a ranking.
Data from Invesco; prices and returns from market data. Page updated October 29, 2026. Holdings and figures change over time. For information only — not investment advice.